Sarepta Therapeutics

Youtube Subscribe

Open: 121.41 Close: 122.77 Change: 1.36

The stock market through the eyes of an AI: Sarepta Therapeutics Stock.

The game is changing. There is a new strategy to evaluate Sarepta Therapeutics fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Sarepta Therapeutics are: Sarepta, Therapeutics, price, result, company, stock, announce, …

Concept Map

Semantic Network

Stock Summary

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company is also developing SRP-.

Today's Summary

Sarepta Therapeutics to announce first quarter 2023 financial results. The 55 analysts offering price forecasts for Sareptptics stock have a median target of 139.93.

Today's News

Sarepta Therapeutics to announce first quarter 2023 financial results. The company is engaged in the discovery and development of free treatment of rare diseases. Sarepta Therapeutics stock has received a consensus rating of buy. The 55 analysts offering price forecasts for Sareptptics stock have a median target of 139.93. Sarepta Therapeutics ( NASDAQ:SRPT – Get Rating ) last announced its quarterly earnings results on Tuesday, February 28th. Goldman Sachs Group lifted their price objective on Sareptpt Therapeuticss from $171.00 to $190.00 and gave the company a “buy” rating. Needham & Company LLC cut their price. objective from $200 to $160. Sarepta Therapeutics Inc stock price today is $122.77. Sareptpt Therapeutic Inc market cap is $10.8B. 52-week high is $159.84 as of April 29, 2023. 52 week low is $61.28. Price-to-E ratio is -15.28. Sarepta Therapeutics appears to have rebounded from last years negative return on equity (117.29%) and a net margin that was 75.4% negative, yielding positive results with an increase of 28.3% in its overall revenue on a year-over-year basis. Sell-side analysts assume that the company will have earnings per share standing at -5.52 for this fiscal year.

Stock Profile

"Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts."

Keywords

How much time have you spent trying to decide whether investing in Sarepta Therapeutics? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Sarepta Therapeutics are: Sarepta, Therapeutics, price, result, company, stock, announce, and the most common words in the summary are: sarepta, therapeutic, cancer, disease, inc, stock, news, . One of the sentences in the summary was: The 55 analysts offering price forecasts for Sareptptics stock have a median target of 139.93.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #sarepta #therapeutic #cancer #disease #inc #stock #news.

Read more →

Youtube Subscribe

---